Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 26, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase transaction:
- Shares Purchased: 1,300,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,230.76 pence per share.
- Treasury Holdings: 498,569,158 shares (representing 9.02% of total voting rights).
- Shares in Issue: 5,526,758,520 (excluding Treasury shares).
Material Changes
The material change reported is the increase in the company's Treasury share holdings following the November 26, 2007 purchase. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed beyond the standard regulatory conformity statement.
Investor Verification Checklist
- Verify the total number of shares in issue (5,526,758,520) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share percentage (9.02%) for voting rights calculations.
- Note that this filing is a notification of a share buyback and does not contain operational or financial performance results.